We are excited to share news from the biotech company Nuevocor, which has announced the successful closing of a $45 million Series B financing round. This funding will support the clinical development of their novel, mechanobiology-centered gene therapy, targeting cardiomyopathies, including those caused by LMNA mutations.
Nuevocor’s lead program focuses on LMNA-associated cardiomyopathy, a progressive and life-threatening form of heart disease. Their innovative approach is designed to address the underlying mechanisms of disease by correcting abnormal mechanobiological signaling—offering the potential for a disease-modifying therapy where currently only symptom management is available.
This milestone not only marks significant progress for Nuevocor but also brings hope to the LMNA cardiac disease community, as it moves the field closer to meaningful treatment options.
👉 Read the full announcement here:
https://www.prnewswire.com/apac/news-releases/nuevocor-closes-us45-million-series-b-financing-for-clinical-development-of-novel-mechanobiology-centered-therapy-for-cardiomyopathy-302446718.html
We will continue to monitor and share updates on Nuevocor’s progress as they move toward clinical trials.